FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4376865366> ?p ?o ?g. }

• W4376865366 endingPage "243" @default.
• W4376865366 startingPage "242" @default.
• W4376865366 abstract "No AccessJournal of UrologyPoint of View1 Aug 2023Point-Counterpoint: Staging Prostate-specific Membrane Antigen Positron Emission Tomography/Computerized Tomography for Detecting Clinically Node Positive Prostate Cancer Jack R. Andrews, Akshay Sood, and Brian F. Chapin Jack R. AndrewsJack R. Andrews *Correspondence: Department of Urology, MD Anderson, Houston, TX (telephone; E-mail Address: [email protected] https://orcid.org/0000-0002-7781-3638 Department of Urology, MD Anderson, Houston, Texas Department of Urology, Mayo Clinic Arizona, Scottsdale, Arizona More articles by this author , Akshay SoodAkshay Sood Department of Urology, MD Anderson, Houston, Texas More articles by this author , and Brian F. ChapinBrian F. Chapin Department of Urology, MD Anderson, Houston, Texas More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003495AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Point-Counterpoint: Staging Prostate-specific Membrane Antigen Positron Emission Tomography/Computerized Tomography for Detecting Clinically Node Positive Prostate Cancer. The Journal of Urology, 210(2), pp. 242–243 REFERENCES 1. . Cancer statistics, 2022. CA Cancer J Clin. 2022; 72(1):7-33. Crossref, Medline, Google Scholar 2. . A systematic review of the role of definitive local treatment in patients with clinically lymph node-positive prostate cancer. Eur Urol Oncol. 2019; 2(3):294-301. Crossref, Medline, Google Scholar 3. . The role of radical prostatectomy and lymph node dissection in clinically node positive patients. Front Oncol. 2019; 9:1395. Crossref, Medline, Google Scholar 4. . Advanced prostate cancer: AUA/ASTRO/SUO guideline PART I. J Urol. 2021; 205(1):14-21. Link, Google Scholar 5. . Efficacy of local treatment in prostate cancer patients with clinically pelvic lymph node-positive disease at Initial diagnosis. Eur Urol. 2018; 73(3):452-461. Crossref, Medline, Google Scholar 6. . Failure-free survival and radiotherapy in patients with newly diagnosed nonmetastatic prostate cancer: data from patients in the control arm of the STAMPEDE trial. JAMA Oncol. 2016; 2(3):348-357. Crossref, Medline, Google Scholar 7. . Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet. 2022; 399(10323):447-460. Crossref, Medline, Google Scholar 8. . Outcomes of primary lymph node staging of intermediate and high risk prostate cancer with 68Ga-PSMA positron emission tomography/computerized tomography compared to histological correlation of pelvic lymph node pathology. J Urol. 2019; 201(4):815-820. Link, Google Scholar 9. . Diagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: a multicenter prospective phase 3 imaging trial. JAMA Oncol. 2021; 7(11):1635-1642. Crossref, Medline, Google Scholar 10. . A phase 2/3 prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET/CT with 18F-DCFPyL in prostate cancer patients (OSPREY). J Urol. 2021; 206(1):52-61. Link, Google Scholar 11. . Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020; 395(10231):1208-1216. Crossref, Medline, Google Scholar 12. . Combination of androgen deprivation therapy with radical local therapy versus androgen deprivation therapy alone for newly diagnosed oligometastatic prostate cancer: a phase II randomized controlled trial. Eur Urol Oncol. 2022; 5(5):519-525. Crossref, Medline, Google Scholar 13. . NCCN guidelines insights: prostate cancer, Version 1.2021. J Natl Compr Canc Netw. 2021; 19(2):134-143. Crossref, Medline, Google Scholar 14. . Assessing the accuracy of [(18)F]PSMA-1007 PET/CT for primary staging of lymph node metastases in intermediate- and high-risk prostate cancer patients. EJNMMI Res. 2022; 12(1):48. Crossref, Medline, Google Scholar Support: None. Conflict of Interest: The Authors have no conflicts of interest to disclose. Ethics Statement: This study was deemed exempt from Institutional Review Board review. Author Contributions: Conception and design: JRA, AS, BFC; Data analysis and interpretation: BFC; Critical revision of the manuscript for scientific and factual content: JRA, AS, BFC; Drafting the manuscript: JRA, AS, BFC; Supervision: JRA, BFC; Literature search: AS. © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 210Issue 2August 2023Page: 242-243 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Jack R. Andrews Department of Urology, MD Anderson, Houston, Texas Department of Urology, Mayo Clinic Arizona, Scottsdale, Arizona *Correspondence: Department of Urology, MD Anderson, Houston, TX (telephone; E-mail Address: [email protected] More articles by this author Akshay Sood Department of Urology, MD Anderson, Houston, Texas More articles by this author Brian F. Chapin Department of Urology, MD Anderson, Houston, Texas More articles by this author Expand All Support: None. Conflict of Interest: The Authors have no conflicts of interest to disclose. Ethics Statement: This study was deemed exempt from Institutional Review Board review. Author Contributions: Conception and design: JRA, AS, BFC; Data analysis and interpretation: BFC; Critical revision of the manuscript for scientific and factual content: JRA, AS, BFC; Drafting the manuscript: JRA, AS, BFC; Supervision: JRA, BFC; Literature search: AS. Advertisement PDF downloadLoading ..." @default.
• W4376865366 created "2023-05-18" @default.
• W4376865366 creator A5004426786 @default.
• W4376865366 creator A5047183440 @default.
• W4376865366 creator A5081777867 @default.
• W4376865366 date "2023-08-01" @default.
• W4376865366 modified "2023-09-25" @default.
• W4376865366 title "Point-Counterpoint: Staging Prostate-specific Membrane Antigen Positron Emission Tomography/Computerized Tomography for Detecting Clinically Node Positive Prostate Cancer" @default.
• W4376865366 doi "https://doi.org/10.1097/ju.0000000000003495" @default.
• W4376865366 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37194136" @default.
• W4376865366 hasPublicationYear "2023" @default.
• W4376865366 type Work @default.
• W4376865366 citedByCount "0" @default.
• W4376865366 crossrefType "journal-article" @default.
• W4376865366 hasAuthorship W4376865366A5004426786 @default.
• W4376865366 hasAuthorship W4376865366A5047183440 @default.
• W4376865366 hasAuthorship W4376865366A5081777867 @default.
• W4376865366 hasConcept C121608353 @default.
• W4376865366 hasConcept C12582419 @default.
• W4376865366 hasConcept C126322002 @default.
• W4376865366 hasConcept C126838900 @default.
• W4376865366 hasConcept C15744967 @default.
• W4376865366 hasConcept C19417346 @default.
• W4376865366 hasConcept C2775842073 @default.
• W4376865366 hasConcept C2779466945 @default.
• W4376865366 hasConcept C2780192828 @default.
• W4376865366 hasConcept C2780849966 @default.
• W4376865366 hasConcept C2781406297 @default.
• W4376865366 hasConcept C71924100 @default.
• W4376865366 hasConceptScore W4376865366C121608353 @default.
• W4376865366 hasConceptScore W4376865366C12582419 @default.
• W4376865366 hasConceptScore W4376865366C126322002 @default.
• W4376865366 hasConceptScore W4376865366C126838900 @default.
• W4376865366 hasConceptScore W4376865366C15744967 @default.
• W4376865366 hasConceptScore W4376865366C19417346 @default.
• W4376865366 hasConceptScore W4376865366C2775842073 @default.
• W4376865366 hasConceptScore W4376865366C2779466945 @default.
• W4376865366 hasConceptScore W4376865366C2780192828 @default.
• W4376865366 hasConceptScore W4376865366C2780849966 @default.
• W4376865366 hasConceptScore W4376865366C2781406297 @default.
• W4376865366 hasConceptScore W4376865366C71924100 @default.
• W4376865366 hasIssue "2" @default.
• W4376865366 hasLocation W43768653661 @default.
• W4376865366 hasLocation W43768653662 @default.
• W4376865366 hasOpenAccess W4376865366 @default.
• W4376865366 hasPrimaryLocation W43768653661 @default.
• W4376865366 hasRelatedWork W1979570009 @default.
• W4376865366 hasRelatedWork W1989171469 @default.
• W4376865366 hasRelatedWork W1995011828 @default.
• W4376865366 hasRelatedWork W2007050830 @default.
• W4376865366 hasRelatedWork W2107251918 @default.
• W4376865366 hasRelatedWork W2111238914 @default.
• W4376865366 hasRelatedWork W2114399000 @default.
• W4376865366 hasRelatedWork W2138931800 @default.
• W4376865366 hasRelatedWork W2305959020 @default.
• W4376865366 hasRelatedWork W2786928931 @default.
• W4376865366 hasVolume "210" @default.
• W4376865366 isParatext "false" @default.
• W4376865366 isRetracted "false" @default.
• W4376865366 workType "article" @default.